Bone Regeneration in Maxillary Sinus Augmentation Using Advanced Platelet-Rich Fibrin (A-PRF) and Plasma Rich in Growth Factors (PRGF): A Pilot Randomized Controlled Trial.

The purpose of this pilot randomized controlled trial was to analyze and compare the effects of advanced platelet-rich fibrin (A-PRF) and plasma rich in growth factors (PRGF), combined with deproteinized bovine bone mineral (DBBM), in bone regeneration outcomes in maxillary sinus augmentation (MSA) procedures. The maxillary sinuses of 15 patients were grafted with DBBM alone (control group), DBBM mixed with A-PRF (PRF group), or DBBM mixed with PRGF (PRGF group). After a 6-month healing period, bone core biopsy samples were collected prior to implant placement for histologic and histomorphometric analyses, evaluating the mean percentages of mineralized tissue (MT), remaining bone graft material (RBGM), and nonmineralized tissue (NMT). Mean MT was 20.33% ± 11.50% for the control group, 32.20% ± 7.29% for the PRF group, and 34.80% ± 6.83% for the PRGF group. Mean RBGM was 24.00% ± 7.94% for the control group, 26.00% ± 7.78% for the PRF group, and 15.80% ± 8.23% for the PRGF group. Mean NMT was 55.66% ± 7.77% for the control group, 41.40% ± 8.32% for the PRF group, and 49.60% ± 5.68% for the PRGF group. No statistically significant differences (P > .05) were seen across the three groups for MT, RBGM, and NT. These findings suggest that adding A-PRF and PRGF to DBBM does not enhance new bone formation outcomes in maxillary sinus augmentation procedures. None of the two platelet concentrates were superior to the other in any of the variables assessed. [ABSTRACT FROM AUTHOR]